In 2009, Merck & Co.’s PD1-blocking antibody pembrolizumab was in development limbo. A decade on, the immuno-oncology drug is Merck’s crown jewel, with more than 20 approvals in 15 tumour types and revenues that are expected to reach US$10 billion this year. For Roger Perlmutter — an immunologist, president of Merck Research Laboratories and executive vice-president of Merck & Co. — this success was not always a sure thing. On the fifth anniversary of the FDA’s approval of pembrolizumab, he spoke with Asher Mullard about remaining immuno-oncology opportunities and questions.

中文翻译：

---

罗杰·珀尔默特（Roger Perlmutter）。

2009年，默克公司的PD1阻断抗体pembrolizumab处于发展边缘。十年以来，这种免疫肿瘤药物是默克公司的皇冠上的明珠，在15种肿瘤类型中获得了20多个批准，预计今年的收入将达到100亿美元。对于免疫学家，默克研究实验室总裁，默克公司执行副总裁罗杰·珀尔默特（Roger Perlmutter）而言，这种成功并不总是确定的。在FDA批准派姆单抗治疗五周年之际，他与Asher Mullard谈了有关剩余的免疫肿瘤学机会和问题。